title: Mediastinal seminoma in a patient with Wiskott-Aldrich syndrome.
abstract: Shortness of breath developed in an 18-year-old man with Wiskott-Aldrich syndrome, and he was found to have a large mediastinal mass. The gallium scan was positive, and biopsy indicated a seminoma. After treatment with four cycles of chemotherapy, the mass completely resolved. Despite severe thrombocytopenia, he required only two platelet transfusions during therapy. Although lymphomas make up the vast majority of mediastinal tumors in patients with Wiskott-Aldrich syndrome, a positive gallium scan should not preclude the diagnosis of seminoma or the need for confirmatory tissue diagnosis. This report shows the possibility of uneventful and successful treatment of malignancy in a patient with Wiskott-Aldrich syndrome and severe thrombocytopenia.
authors.affiliation: Department of Pediatrics, Section of Pediatric Hematology-Oncology, The University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0938, USA.
authors.forename: Kristen M
authors.initials: KM
authors.lastname: Snyder
authors.forename: Mark A
authors.initials: MA
authors.lastname: Rubin
authors.forename: Barry L
authors.initials: BL
authors.lastname: Shulkin
authors.forename: Raymond J
authors.initials: RJ
authors.lastname: Hutchinson
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Wechsler
mesh_terms: D000293:Adolescent; D000707:Anaphylaxis / Q000139:chemically induced; D000744:Anemia, Hemolytic, Autoimmune / Q000150:complications / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005710:Gallium Radioisotopes; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008297:Male; D008479:Mediastinal Neoplasms / Q000000981:diagnostic imaging / Q000209:etiology* / Q000235:genetics; D009386:Neoplastic Syndromes, Hereditary; D011241:Prednisone / Q000008:administration & dosage; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012074:Remission Induction; D018239:Seminoma / Q000000981:diagnostic imaging / Q000209:etiology* / Q000235:genetics; D014750:Vincristine / Q000008:administration & dosage; D014923:Wiskott-Aldrich Syndrome / Q000150:complications
chemical_list: D005710:Gallium Radioisotopes; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D019275:Radiopharmaceuticals; D001761:Bleomycin; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin; D011241:Prednisone